Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Work In Process (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Work In Process for 6 consecutive years, with $16.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Work In Process rose 154.79% year-over-year to $16.5 million, compared with a TTM value of $16.5 million through Dec 2025, up 154.79%, and an annual FY2025 reading of $16.5 million, up 154.79% over the prior year.
  • Work In Process was $16.5 million for Q4 2025 at Cytek Biosciences, up from $6.7 million in the prior quarter.
  • Across five years, Work In Process topped out at $16.5 million in Q4 2025 and bottomed at $1.5 million in Q1 2022.
  • Average Work In Process over 5 years is $6.1 million, with a median of $6.0 million recorded in 2024.
  • The sharpest move saw Work In Process surged 201.39% in 2023, then plummeted 48.56% in 2024.
  • Year by year, Work In Process stood at $2.3 million in 2021, then soared by 113.19% to $4.9 million in 2022, then skyrocketed by 113.48% to $10.5 million in 2023, then crashed by 37.94% to $6.5 million in 2024, then skyrocketed by 154.79% to $16.5 million in 2025.
  • Business Quant data shows Work In Process for CTKB at $16.5 million in Q4 2025, $6.7 million in Q3 2025, and $7.7 million in Q2 2025.